{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:47:39Z","timestamp":1791838059607,"version":"4.3.4"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.09.008","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T06:04:53Z","timestamp":1789365893000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Supportive Care in Multiple Myeloma: Evidence-Based Recommendations From the Intergroupe Francophone du My\u00e9lome (IFM)"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2163","authenticated-orcid":false,"given":"Laurent","family":"Frenzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Godmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6734-413X","authenticated-orcid":false,"given":"Alexis","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Sonntag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9469-8336","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chalopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Decaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanaz","family":"Louni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0879-6261","authenticated-orcid":false,"given":"Emilie","family":"Chalayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-9428","authenticated-orcid":false,"given":"Murielle","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2026.09.008_bib0001","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.clml.2026.09.008_bib0002","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2026.09.008_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11102720","article-title":"Incidence of venous thromboembolism in multiple myeloma patients across different regimens: role of procoagulant microparticles and cytokine release","volume":"11","author":"Gidaro","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.clml.2026.09.008_bib0004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.008_bib0005","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clml.2020.11.015","article-title":"Thromboembolism incidence and risk factors in multiple myeloma after first exposure to immunomodulatory drug-based regimens","volume":"21","author":"Patel","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"10.1016\/j.clml.2026.09.008_bib0006","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2026.09.008_bib0007","first-page":"588","article-title":"External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs","volume":"200","author":"Dima","year":"2023","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.clml.2026.09.008_bib0008","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood.2022015727","article-title":"Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score","volume":"140","author":"Chakraborty","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.09.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102571","article-title":"Multiple myeloma: retrospective assessment of routine thromboprophylaxis and utility of thrombotic risk scores","volume":"8","author":"Fernandez-Vargas","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"10.1016\/j.clml.2026.09.008_bib0010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.19017","article-title":"Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: a systematic review and updated meta-analysis","volume":"203","author":"Costa","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.09.008_bib0011","first-page":"1","article-title":"Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: a prospective cohort study","volume":"215","author":"Sayar","year":"2022","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.clml.2026.09.008_bib0012","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ajh.25459","article-title":"Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study","volume":"94","author":"Pegourie","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.09.008_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102865","article-title":"A systematic review of direct oral anticoagulants for thromboprophylaxis in multiple myeloma","volume":"9","author":"Codreanu","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"10.1016\/j.clml.2026.09.008_bib0014","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.jtha.2025.06.012","article-title":"Thromboembolism in transplant-ineligible multiple myeloma patients on triplet\/quadruplet therapy: a post hoc analysis of the BENEFIT trial","volume":"23","author":"Chalayer","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clml.2026.09.008_bib0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.thromres.2023.11.021","article-title":"Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: results of a large survey and clinical guidance recommendations from the IFM group","volume":"233","author":"Frenzel","year":"2024","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.clml.2026.09.008_bib0016","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.clml.2026.09.008_bib0017","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: from biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.09.008_bib0018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.clml.2026.09.008_bib0019","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00774-023-01403-4","article-title":"Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents","volume":"41","author":"Teramachi","year":"2023","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.clml.2026.09.008_bib0020","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"9757","key":"10.1016\/j.clml.2026.09.008_bib0021","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.clml.2026.09.008_bib0022","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1182\/blood-2013-04-498139","article-title":"The impact of response on bone-directed therapy in patients with multiple myeloma","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2026.09.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30559-3","article-title":"Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group","volume":"22","author":"Terpos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.008_bib0024","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.008_bib0025","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/10428194.2014.924117","article-title":"Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma","volume":"56","author":"Sanfilippo","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.clml.2026.09.008_bib0026","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2026.09.008_bib0027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2026.09.008_bib0028","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/imj.16100","article-title":"Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma","volume":"53","author":"Teh","year":"2023","journal-title":"Intern Med J"},{"issue":"12","key":"10.1016\/j.clml.2026.09.008_bib0029","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.09.008_bib0030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ejh.13374","article-title":"Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: systematic review and meta-analysis","volume":"104","author":"Mohyuddin","year":"2020","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2026.09.008_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.clml.2026.09.008_bib0032","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/bloodadvances.2023011231","article-title":"Immunoglobulin replacement versus prophylactic antibiotics for hypogammaglobulinaemia secondary to haematological malignancy","volume":"8","author":"McQuilten","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.09.008_bib0033","unstructured":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 (ANSM). Recommandations pour l'utilisation des immunoglobulines; 2025. https:\/\/ansm.sante.fr."},{"issue":"12","key":"10.1016\/j.clml.2026.09.008_bib0034","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clml.2025.06.014","article-title":"Indirect comparison of linvoseltamab versus teclistamab for the treatment of triple-class exposed relapsed\/refractory multiple myeloma","volume":"25","author":"Lee","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"10.1016\/j.clml.2026.09.008_bib0035","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2026.09.008_bib0036","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.clml.2026.09.008_bib0037","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2026.09.008_bib0038","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.clml.2026.09.008_bib0039","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"S2","key":"10.1016\/j.clml.2026.09.008_bib0040","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1002\/ajh.26766","article-title":"Prevention of infections including vaccination strategies in multiple myeloma","volume":"98","author":"Ludwig","year":"2023","journal-title":"Am J Hematol"},{"issue":"2S","key":"10.1016\/j.clml.2026.09.008_bib0041","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.bulcan.2023.05.007","article-title":"Vaccination of allogeneic haematopoietic stem cell transplant recipients: guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"111","author":"Conrad","year":"2024","journal-title":"Bull Cancer"},{"issue":"3","key":"10.1016\/j.clml.2026.09.008_bib0042","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2026.09.008_bib0043","article-title":"Strat\u00e9gie de vaccination contre les infections invasives \u00e0 pneumocoques chez l'adulte: place du vaccin 21-valent (VPC21, Capvaxive)","author":"Autorit\u00e9 de Sant\u00e9","year":"2025","journal-title":"Saint-Denis: HAS"},{"issue":"10","key":"10.1016\/j.clml.2026.09.008_bib0044","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.clml.2026.09.008_bib0045","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ctrv.2009.08.002","article-title":"Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma","volume":"35","author":"Katodritou","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2026.09.008_bib0046","article-title":"Anaemia in multiple myeloma: evolving insights into bone marrow microenvironment-driven pathogenesis and targeted management","author":"Li","year":"2026","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.clml.2026.09.008_bib0047","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1200\/JCO.2002.07.177","article-title":"Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology","volume":"20","author":"Rizzo","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.008_bib0048","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2007.14.3396","article-title":"Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology\/American Society of Hematology clinical practice guideline update","volume":"26","author":"Rizzo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.008_bib0049","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1200\/JCO.2010.29.2201","article-title":"American Society of Clinical Oncology\/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer","volume":"28","author":"Rizzo","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.09.008_bib0050","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","article-title":"Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials","volume":"373","author":"Bohlius","year":"2009","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clml.2026.09.008_bib0051","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/jth.15758","article-title":"Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: lessons from the substudy of IFM\/DFCI 2009 cohort","volume":"20","author":"Chalayer","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.clml.2026.09.008_bib0052","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cncr.26302","article-title":"Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis","volume":"118","author":"Anaissie","year":"2012","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.clml.2026.09.008_bib0053","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.18.02142","article-title":"Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH Clinical Practice Guideline update","volume":"37","author":"Bohlius","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.09.008_bib0054","first-page":"179","article-title":"Physical activity in multiple myeloma: a review of the current literature","volume":"25","author":"Hillengass","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.clml.2026.09.008_bib0055","first-page":"217","article-title":"Safety, feasibility, and efficacy of exercise interventions for people with multiple myeloma: a systematic review","volume":"31","author":"Nicol","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2026.09.008_bib0056","unstructured":"Association Francophone des Soins Oncologiques de Support (AFSOS). Activit\u00e9 physique et cancer. R\u00e9f\u00e9rentiel AFSOS. Paris, France: AFSOS; updated May 2024. Available at: https:\/\/www.onco-hdf.fr\/app\/uploads\/2024\/08\/Referentiels-en-SOS-Activite-Physique-et-cancer-AFSOS-2024.pdf. Accessed: October 6, 2026."},{"key":"10.1016\/j.clml.2026.09.008_bib0057","article-title":"Physical activity guidelines in oncology: a systematic review of current recommendations","volume":"196","author":"Avancini","year":"2025","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.clml.2026.09.008_bib0058","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1016\/j.clml.2022.07.002","article-title":"Longitudinal real-world neuropathy and patient-reported outcomes with bortezomib and lenalidomide in newly diagnosed multiple myeloma","volume":"22","author":"Major","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2026.09.008_bib0059","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"28","key":"10.1016\/j.clml.2026.09.008_bib0060","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026032945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:04:43Z","timestamp":1791835483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026032945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":60,"alternative-id":["S2152265026032945"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Supportive Care in Multiple Myeloma: Evidence-Based Recommendations From the Intergroupe Francophone du My\u00e9lome (IFM)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}